Intellia Therapeutics shares last traded at $15.5270, with a volume of 6,886,122 shares traded. William Blair downgraded shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, October 27th. Wall Street Zen cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 18th. Get Intellia Therapeutics alerts:View Our Latest Report on Intellia TherapeuticsIntellia Therapeutics Stock Up 0.6%The stock has a fifty day simple moving average of $10.34 and a two-hundred day simple moving average of $12.95. See AlsoReceive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.